Toulouse

• A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated A … Recruiting
  2023-503679-12-00 1 2022-11-21 Relapsed or Refractory Multiple Myeloma
• INNOVATIVE TREATMENT OF SCARRED VOCAL FOLDS BY LOCAL INJECTION OF AUTOLOGOUS ADIPOSE-DERIVED STROMAL VASCULAR FRACTION: EFFICACY VERSUS PLAC … Recruiting
  2024-517384-24-00 4 2022-09-22 SCARRED VOCAL FOLDS
• ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care Recruiting
  2024-513327-16-00 5 2022-09-20 Intensive care
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 5 2022-08-31 chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte … Recruiting
  2024-515945-40-00 10 2022-05-02 Non small cell lung cancer
• A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic … Recruiting
  2024-516010-38-00 1 2022-04-25 Participants with Locally Advanced or Metastatic HER2-Expressing Cance
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting
  2022-503068-34-00 4 2022-04-06 Metastatic Gastrointestinal Stromal Tumor
• A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting
  2024-511793-71-00 7 2022-02-28 Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tu
• Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting
  2024-511609-44-00 10 2022-02-03 Rectum cancer
• API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P … Recruiting
  2024-513191-17-00 4 2022-02-03 autoimmune hemolytic anemia
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: … Recruiting
  2024-518594-33-00 5 2021-11-18 mastocytosis
• HARBOR: Study of BLU-263 for Indolent Systemic Mastocytosis Recruiting
  2024-516728-32-00 10 2021-10-29 Indolent Systemic Mastocytosis and SSM
• Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruiting
  2024-514843-27-00 6 2021-10-11 Severe asthma
• Intra-arterial hepatic (IAH) infusion of radiolabelled somatostatin analogs in GEP-NET patients with dominant liver metastases Recruiting
  2024-514785-39-00 4 2021-09-24 Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults
• IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre … Recruiting
  2024-517215-67-00 5 2021-06-11 Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
• Short Treatment With Omalizumab for Severe Asthma (SHORTEN) Recruiting
  2024-513427-17-00 6 2021-05-20 Well controlled severe allergic asthma
• Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast C … Recruiting
  2023-505923-30-00 4 2021-05-11 Patients with hormone-receptor positive (HR+) and human epidermal grow
• Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL) Recruiting
  2023-505483-11-00 6 2021-05-02 Brain abscess
• AGADIR : Atezolizumab combined with EIK10001 (BDB001) and Immunogenic Radiotherapy in Patients with Advanced Solid Tumors Recruiting
  2023-509492-16-00 4 2021-03-30 Adult participants with metastatic (advanced) solid tumors.
• Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease: multicentric randomized phase … Recruiting
  2024-511868-83-00 5 2021-02-05 Antisynthetase syndrome-related interstitial lung disease

Showing 313–336 of 642 trials